<DOC>
	<DOCNO>NCT00016250</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase II trial compare effectiveness two different regimen Ro 31-7453 treating patient recurrent refractory metastatic colorectal cancer .</brief_summary>
	<brief_title>Ro 31-7453 Treating Patients With Recurrent Refractory Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare objective disease rate patient recurrent refractory metastatic colorectal cancer treat two dose schedule Ro 31-7453 . - Compare safety tolerability regimens patient . - Compare response duration patient treat regimen . - Compare time progression time treatment failure patient treat regimen . - Determine pharmacokinetic profile Ro 31-7453 major metabolite patient . - Compare overall survival patient treat regimen . OUTLINE : This randomize , open label , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive oral Ro 31-7453 twice daily day 1-4 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . - Arm II : Patients receive oral Ro 31-7453 twice daily day 1-14 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 28 day every 3 month . PROJECTED ACCRUAL : Approximately 160 patient ( 49 per treatment arm plus 61 additional patient arm determine effective ) accrue study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma colon rectum Bidimensionally measurable disease At least 2.0 x 2.0 cm Failed prior fluoropyrimidine irinotecan chemotherapy adjuvant metastatic setting Must disease progression receive chemotherapy OR If receive fluorouracil without irinotecan adjuvant setting , must also fail therapy agent metastatic setting ( unless manifest metastatic disease adjuvant therapy ) No know CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 9 g/dL Absolute neutrophil count least 1,500/mm^3 WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN ( 5 time ULN liver metastasis present ) Alkaline phosphatase great 2.5 ULN ( 5 time ULN bone liver metastases present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV congestive heart failure No myocardial infarction within past 6 month Gastrointestinal : No bowel obstruction No active uncontrolled malabsorption syndrome Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No prior malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer No active cancer , include stable disease adjuvant therapy No medical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy At least 2 week since prior biologic therapy recover Chemotherapy : See Disease Characteristics No 2 prior cytotoxic chemotherapy regimens metastatic disease Monoclonal antibody ( MOAB ) therapy antiangiogenic agent include prior cytotoxic chemotherapy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : No prior total gastrectomy Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>